{"nctId":"NCT02463071","briefTitle":"AZD0585 Phase III Long-term Study in Japan","startDateStruct":{"date":"2015-06-10","type":"ACTUAL"},"conditions":["Hypertriglyceridemia"],"count":383,"armGroups":[{"label":"AZD0585 2g group","type":"EXPERIMENTAL","interventionNames":["Drug: AZD0585","Drug: AZD0585 placebo"]},{"label":"AZD0585 4g group","type":"EXPERIMENTAL","interventionNames":["Drug: AZD0585"]},{"label":"Placebo control group","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: AZD0585 placebo"]}],"interventions":[{"name":"AZD0585","otherNames":["Epanova"]},{"name":"AZD0585 placebo","otherNames":["Corn oil"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Japanese men or women, â‰¥20 years of age.\n* Subjects must meet all of the following criteria;\n\n  1. Fasting triglyceride level: average of Visit 2 and Visit 3 must be in the range 150 - 499 mg/dL\n  2. %TG change between Visit 2 and Visit 3 must be within 30%\n  3. %LDL-C change between Visit 2 and Visit 3 must be within 25%\n\nKey Exclusion Criteria:\n\n* Allergy or intolerance to omega-3 fatty acids and omega-3-acid ethyl esters.\n* Known lipoprotein lipase impairment or deficiency, or Apolipoprotein C-II deficiency or familial dysbetalipoproteinemia.\n* Current or history of pancreatitis.\n* Type I diabetes mellitus, use of insulin, or haemoglobin A1c \\>10% at Visit 1.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Efficacy of AZD0585 by Assessment of Percent Change in Serum Triglycerides","description":"To demonstrate the efficacy of AZD0585 2 g and 4 g compared to placebo (corn oil) in Japanese patients with hypertriglyceridemia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.57","spread":"1.70"},{"groupId":"OG001","value":"-21.78","spread":"1.95"},{"groupId":"OG002","value":"11.15","spread":"4.65"}]}]}]},{"type":"PRIMARY","title":"Safety of AZD0585 by Assessment of Adverse Events in Patients","description":"To evaluate the long-term (up to 52 weeks) safety of AZD0585 in Japanese patients with hypertriglyceridemia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"135","spread":null},{"groupId":"OG002","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"36","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy of AZD0585 by Assessment of Percent Change in Serum Lipid Profile","description":"To assess the efficacy of AZD0585 2 g and 4 g compared to placebo (corn oil). The serum lipid profile includes total cholesterol, High-density lipoprotein cholesterol, Low-density lipoprotein cholesterol,Very low-density lipoprotein cholesterol and Non-high-density lipoprotein cholesterol.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.34","spread":"0.78"},{"groupId":"OG001","value":"-1.95","spread":"1.29"},{"groupId":"OG002","value":"2.31","spread":"1.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.45","spread":"1.18"},{"groupId":"OG001","value":"-2.17","spread":"1.91"},{"groupId":"OG002","value":"2.90","spread":"2.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.64","spread":"0.83"},{"groupId":"OG001","value":"1.54","spread":"0.86"},{"groupId":"OG002","value":"1.33","spread":"1.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.33","spread":"1.05"},{"groupId":"OG001","value":"-3.11","spread":"1.74"},{"groupId":"OG002","value":"3.05","spread":"1.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.18","spread":"2.62"},{"groupId":"OG001","value":"-18.35","spread":"2.73"},{"groupId":"OG002","value":"7.06","spread":"3.84"}]}]}]},{"type":"SECONDARY","title":"Efficacy of AZD0585 by Assessment of Percent Changes in Plasma Fatty Acids Profile.","description":"To assess the efficacy of AZD0585 2 g and 4 g compared to placebo (corn oil) . The plasma fatty acids profile includes eicosapentaenoic acid, docosahexaenoic acid, arachidonic acid and eicosapentaenoic acid per arachidonic acid rate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"153.06","spread":"10.40"},{"groupId":"OG001","value":"265.34","spread":"15.86"},{"groupId":"OG002","value":"3.60","spread":"10.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.21","spread":"2.50"},{"groupId":"OG001","value":"20.10","spread":"2.45"},{"groupId":"OG002","value":"0.13","spread":"4.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.26","spread":"1.33"},{"groupId":"OG001","value":"-10.00","spread":"1.39"},{"groupId":"OG002","value":"0.86","spread":"1.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"169.64","spread":"11.12"},{"groupId":"OG001","value":"319.90","spread":"20.02"},{"groupId":"OG002","value":"-2.19","spread":"9.23"}]}]}]},{"type":"SECONDARY","title":"Efficacy of AZD0585 by Assessment of Percent Changes in Apolipoproteins Profile","description":"To assess the efficacy of AZD0585 2 g and 4 g compared to placebo (corn oil) . Apolipoproteins include Apolipoprotein A-I, Apolipoprotein A-II, Apolipoprotein B, Apolipoprotein B48, Apolipoprotein C-II, Apolipoprotein C-III and Apolipoprotein E.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":"0.84"},{"groupId":"OG001","value":"-0.42","spread":"0.83"},{"groupId":"OG002","value":"0.55","spread":"1.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.20","spread":"0.85"},{"groupId":"OG001","value":"-5.01","spread":"0.80"},{"groupId":"OG002","value":"0.31","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73","spread":"1.05"},{"groupId":"OG001","value":"-0.30","spread":"1.07"},{"groupId":"OG002","value":"2.60","spread":"1.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.87","spread":"4.86"},{"groupId":"OG001","value":"0.94","spread":"5.26"},{"groupId":"OG002","value":"41.58","spread":"17.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.98","spread":"1.82"},{"groupId":"OG001","value":"-6.20","spread":"2.26"},{"groupId":"OG002","value":"5.49","spread":"2.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.50","spread":"2.03"},{"groupId":"OG001","value":"-5.47","spread":"2.20"},{"groupId":"OG002","value":"5.56","spread":"2.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.25","spread":"2.08"},{"groupId":"OG001","value":"6.27","spread":"2.06"},{"groupId":"OG002","value":"9.67","spread":"3.08"}]}]}]},{"type":"SECONDARY","title":"Efficacy of AZD0585 by Assessment of Percent Changes in Small Dense LDL and LDL-C/Apo B Ratio","description":"To assess the efficacy of AZD0585 2 g and 4 g compared to placebo (corn oil).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.49","spread":"2.08"},{"groupId":"OG001","value":"-1.72","spread":"2.05"},{"groupId":"OG002","value":"5.19","spread":"2.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":"0.99"},{"groupId":"OG001","value":"-1.77","spread":"1.63"},{"groupId":"OG002","value":"0.66","spread":"1.41"}]}]}]},{"type":"SECONDARY","title":"Efficacy of AZD0585 by Assessment of Percent Changes in Lp(a), RLP-C, PCSK9, and Hs-CRP","description":"To assess the efficacy of AZD0585 2 g and 4 g compared to placebo (corn oil).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.84","spread":"4.31"},{"groupId":"OG001","value":"22.69","spread":"3.97"},{"groupId":"OG002","value":"3.18","spread":"5.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.85","spread":"6.84"},{"groupId":"OG001","value":"54.86","spread":"55.30"},{"groupId":"OG002","value":"53.80","spread":"16.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.20","spread":"2.79"},{"groupId":"OG001","value":"0.51","spread":"3.10"},{"groupId":"OG002","value":"13.53","spread":"4.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119.94","spread":"59.65"},{"groupId":"OG001","value":"15.24","spread":"19.29"},{"groupId":"OG002","value":"69.61","spread":"42.95"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":152},"commonTop":["Nasopharyngitis","Diarrhoea","Bronchitis","Back pain","Gastroenteritis"]}}}